Physician profile
Danial Khalifa
NPI 1467899898
$5,035.58
in general payments reported to CMS, 2019-2025
21 companies · $242 in 2025
The $242 reported for 2025 was less than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $110 · 2021: $1,303 · 2022: $2,751 · 2023: $230 · 2024: $399 · 2025: $242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $871.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $870.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acera Surgical, INC. | $2,698.32 | 2022 | |
| Liberty Surgical INC. | $745.23 | 2021 | |
| Organogenesis INC. | $439.89 | 2020-2025 | Puraply Wound Matrix, Puraply |
| Arthrex, INC. | $310.00 | 2021 | |
| Medtronic, INC. | $195.62 | 2024-2025 | Vanta Adaptivestim, Intellis Adaptivestim |
| Zimmer Biomet Holdings, INC. | $154.73 | 2021 | |
| Novo Nordisk INC | $106.30 | 2023 | Wegovy |
| Smith+Nephew, INC. | $52.97 | 2021-2024 | Collagenase Santyl |
| Integra Lifesciences Corporation | $52.49 | 2020-2023 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Paratek Pharmaceuticals, INC. | $50.43 | 2025 | Nuzyra |
| Averitas Pharma INC. | $42.38 | 2023-2024 | Qutenza |
| Reapplix INC. | $25.44 | 2022 | |
| Djo, LLC | $23.44 | 2024 | Donjoy |
| Akebia Therapeutics INC | $20.64 | 2025 | Vafseo |
| Convatec INC. | $20.27 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baudax Bio INC. | $18.78 | 2021 | |
| Hydrofera LLC | $18.57 | 2021 | |
| Eclipse Technology Solutions INC. | $17.19 | 2023 | |
| Solventum Corporation | $15.63 | 2025 | Activ.A.C. |
| Amgen INC. | $14.31 | 2024 | Krystexxa |
| Misonix INC | $12.95 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danial Khalifa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.